To determine the incorrect statement regarding locally advanced carcinoma breast, let's analyze each option:
Locally advanced breast cancer (LABC) forms a significant majority of breast cancer cases diagnosed in India. This is often attributed to factors like delayed diagnosis and lack of widespread screening programs compared to developed nations. Therefore, this statement is generally considered accurate.
The clinical definition of locally advanced breast cancer typically involves tumors categorized as $T_3$ (tumor size > 5 cm) or $T_4$ (tumor involves chest wall or skin), regardless of the lymph node status (N), as long as there are no distant metastases ($M_0$). This statement correctly describes the staging criteria for LABC.
Neoadjuvant chemotherapy, administered before definitive surgery, is a cornerstone in managing locally advanced breast cancer. It aims to shrink the tumor mass, potentially down-stage the disease, increase the likelihood of surgical success (including breast conservation in some cases), and assess tumor response to systemic therapy. This statement accurately reflects the function of neoadjuvant chemotherapy.
While radical mastectomy was historically a primary surgical option, it is not the current treatment of choice for most locally advanced breast cancer cases. Modern treatment paradigms prioritize neoadjuvant systemic therapy followed by surgery. Surgical options are often less radical than the traditional Halsted radical mastectomy (which removes breast tissue, pectoral muscles, and axillary lymph nodes). The choice depends on response to neoadjuvant therapy and extent of disease, often involving modified mastectomy or breast-conserving surgery where appropriate, alongside adjuvant therapies. Thus, stating radical mastectomy is the 'treatment of choice' is incorrect.
Based on the analysis, the statement that is not correct with reference to locally advanced carcinoma breast is that Radical Mastectomy is the treatment of choice.